TH News and Press, Target Hospitality Corp. From 02/21/24

Positive Adjusted EBITDA* for Q4 2023 more than doubles from Q3 2023 to $5 million (Net Loss of $2.8 million) leading to a significant turnaround for the full year versus 2022 Record quarterly revenue of $23.5 million and annual revenue of $81.8 million Updated Phase 1 tri...

Publication pinpoints triggering of cGAS/STING pathway to activate immune defense mechanisms, as well as potentiation of anti-PD-L1 immune-mediated tumor cell killing, in triple-negative breast cancer xenograft model Weekly administration of single agent sudocetaxel zendusortide demon...

Target Hospitality Announces Appointment of John C. Dorman to Board of Directors PR Newswire THE WOODLANDS, Texas , Feb. 20, 2024 /PRNewswire/ -- Target Hospitality Corp. ("Target Hospitality," "Target" or the "Company") (Nasdaq: TH), one of North America's large...

Study milestone further extends momentum for Company’s lead PDC candidate and oncology clinical development program MONTREAL, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biop...

2024-02-12 09:28:18 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips There are many types of companies in the financial markets, firstly from different sectors, and secondly, they can vary according to their capitalization size. Their capitalization can go by va...

2024-02-11 11:25:00 ET Summary Jackson Peak is an alternative investment firm that manages a single, concentrated, long / short equity portfolio. The firm’s objective is to deliver attractive risk-adjusted, absolute returns. Q4 was a strong quarter for Jackson Peak, which r...

MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will re...

FDA requesting clarifications around chemistry, manufacturing and controls and additional information related to immunogenicity CRL does not impact commercial availability of EGRIFTA SV ® , the F4 formulation of tesamorelin, the only medication approved in the U.S. ...

2024-01-23 08:02:31 ET More on Target Hospitality Target Hospitality: Growth And Financial Strength On The Back Of A Single Relationship Target Hospitality: Financial Strength Ascends While Stock Trends Downward Target Hospitality GAAP EPS of $0.43 in-line, revenue o...

FDA continues to review the file past the Prescription Drug User Fee Act goal date of January 22, 2024 MONTREAL, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company ...